Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview

Brainstorm Cell Therapeutics

12/08/2025 14:14

Brainstorm Cell Therapeutics Inc BCLI.PK  is expected to  show no change in quarterly revenue when it reports  results on August 14 for the period ending June 30 2025

​LSEG's mean analyst estimate for Brainstorm Cell Therapeutics Inc is for a loss of 37 cents per share.

The one available analyst rating on the shares is "hold".

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Brainstorm Cell Therapeutics Inc is $19.76, about 97% above its last closing price of $0.60

This summary was machine generated August 12 at 13:14 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)